PAR-25-299
Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
Summary
Briefing: PAR-25-299 – Interventions to Address Disparities in Liver Diseases and Liver Cancer
Research Focus
This initiative supports multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations experiencing health disparities in the United States. The funder targets racial, ethnic, and socioeconomic disparities in chronic hepatitis B (HBV), chronic hepatitis C (HCV), metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), chronic liver disease (CLD), steatotic liver disease (SLD), cirrhosis, and hepatocellular carcinoma (HCC). Research should develop and test interventions addressing screening, prevention, treatment, management, and survivorship across these conditions. Applicants are encouraged to move beyond individual-level behavior change to include interpersonal, community, and policy-level approaches; incorporate social determinants of health (SDOH); and employ rigorous study designs such as randomized controlled trials, stepped-wedge designs, or cluster-randomized trials. Community-engaged research with shared leadership and collaboration with community organizations, clinicians, and public health entities is strongly encouraged. Projects addressing co-infections (e.g., HIV) and comorbidities (obesity, diabetes, substance use disorder) are of particular interest.
At-a-Glance
- Who can apply: U.S. institutions; no specific career stage restrictions stated.
- Funding & project length: Not stated; standard NIH R01 terms apply.
- Award mechanism: R01 Research Project Grant (clinical trials optional).
- Key dates: Open January 5, 2025; rolling due dates through January 8, 2028 (earliest start dates range from December 2024 to December 2027).
- Best fit for: Public health, epidemiology, implementation science, and clinical researchers designing community-based or health systems interventions for liver disease prevention and treatment in underrepresented populations.
Key Facts
Deadline
Fri, January 7, 2028
Posted
Thu, December 5, 2024
Award / Year (direct costs)
$250,000
Max Total
$1,250,000
Max Duration
5 years
Keywords
Research Areas
Gotchas (4)
FOA was updated March 31, 2025 to align with agency priorities, but no specific changes are detailed. Applicants must 'carefully reread' but the nature of updates is not specified.
85%
Source Text
“This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.”
The FOA emphasizes that 'Interventions that extend beyond modifying individual-level health behavior are needed (i.e., interpersonal, community)' and discourages interventions that focus only on 'incr
80%
Source Text
“Interventions that extend beyond modifying individual-level health behavior are needed (i.e., interpersonal, community). Proposed interventions are encouraged to focus beyond increasing awareness and screening alone to include changes in modifiable factors of liver disease and/or liver cancer incidence and progression.”
The FOA requires projects to be 'U.S. studies of populations experiencing health disparities' and to include 'unique relevant clinical factors' and 'Environmental (e.g., physical, social, built) measu
70%
Source Text
“Projects should include U.S. studies of populations experiencing health disparities and are expected to include unique relevant clinical factors. Environmental (e.g., physical, social, built) measurements, as well as personal and intergenerational histories (e.g., geographic region, birthplace), are also encouraged to further elucidate contextual influences of liver disease and/or liver cancer among populations with disparities.”
The FOA strongly encourages use of 'appropriate intervention study designs, such as parallel group-, stepped-wedge group- or cluster-randomized trial, a rigorous quasi-experimental design' but does no
75%
Source Text
“Investigators proposing to evaluate the effect of an intervention on a health-related biomedical, behavioral, or clinical outcome are strongly encouraged to use appropriate intervention study designs, such as parallel group-, stepped-wedge group- or cluster-randomized trial, a rigorous quasi-experimental design, such as group- or cluster-level regression discontinuity or interrupted time-series, or a rigorous alternative.”